

Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis

Richard N Appleby,¹ Jonathan D Nolan,¹ Ian M Johnston,¹ Sanjeev S Pattni,^{1,2} Jessica Fox,¹ Julian RF Walters¹

To cite: Appleby RN, Nolan JD, Johnston IM, *et al*. Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis. *BMJ Open Gastro* 2017;**4**:e000178. doi:10.1136/bmjgast-2017-000178

Received 1 September 2017
Revised 28 September 2017
Accepted 2 October 2017

ABSTRACT

Background Bile acid diarrhoea (BAD) is a common cause of chronic diarrhoea with a population prevalence of primary BAD around 1%. Previous studies have identified associations with low levels of the ileal hormone fibroblast growth factor 19 (FGF19), obesity and hypertriglyceridaemia. The aim of this study was to identify further associations of BAD.

Methods A cohort of patients with chronic diarrhoea who underwent ⁷⁵selenohomocholic acid taurate (SeHCAT) testing for BAD was further analysed retrospectively. Additional clinical details available from the electronic patient record, including imaging, colonoscopy, chemistry and histopathology reports were used to calculate the prevalence of fatty liver disease, gallstones, colonic neoplasia and microscopic colitis, which was compared for BAD, the primary BAD subset and control patients with diarrhoea.

Findings Of 578 patients, 303 (52%) had BAD, defined as a SeHCAT 7d retention value <15%, with 179 (31%) having primary BAD. 425 had an alanine aminotransferase (ALT) recorded, 184 had liver imaging and 176 had both. Overall, SeHCAT values were negatively associated with ALT ($r_s = -0.19$, $p < 0.0001$). Patients with BAD had an OR of 3.1 for an ALT >31 ng/mL with imaging showing fatty liver ($p < 0.001$); similar figures occurred in the primary BAD group. FGF19 was not significantly related to fatty liver but low levels were predictive of ALT >40 IU/L. In 176 subjects with gallbladder imaging, 27% had gallstones, 7% had a prior cholecystectomy and 34% either of these. The median SeHCAT values were lower in those with gallstones (3.8%, $p < 0.0001$), or gallstones/cholecystectomy (7.2%, $p < 0.001$), compared with normal gallbladder imaging (14%). Overall, BAD had an OR of 2.0 for gallstones/cholecystectomy ($p < 0.05$). BAD was not significantly associated with colonic adenoma/carcinoma or with microscopic colitis.

Interpretation The diagnosis of BAD is associated with fatty liver disease and with gallstones. The reasons for these associations require further investigation into potential metabolic causes.

INTRODUCTION

Bile acid diarrhoea (BAD) is a common disorder characterised by chronic watery diarrhoea and is a consequence of increased delivery of bile acids (BAs) to the colonic

Summary box

What is already known about this subject?

- ▶ Bile acid diarrhoea is a common but under-recognised cause of chronic diarrhoea, which can be diagnosed by the ⁷⁵selenohomocholic acid taurate (SeHCAT) test.
- ▶ Primary bile acid diarrhoea may result from impaired regulation of hepatic bile acid synthesis by the hormone fibroblast growth factor 19, which also has other metabolic actions.
- ▶ The conditions associated with the causes and effects of bile acid diarrhoea are poorly understood.

What are the new findings?

- ▶ A cohort of patients who all had SeHCAT testing to diagnose bile acid diarrhoea was further analysed to investigate specific associated conditions.
- ▶ Markers for fatty liver disease were found more commonly in patients with bile acid diarrhoea.
- ▶ The presence of gallstones, or a previous cholecystectomy, was associated with bile acid diarrhoea.
- ▶ Colonic polyps, cancer and microscopic colitis were not commoner in bile acid diarrhoea.

How might it impact on clinical practice in the foreseeable future?

- ▶ The association of bile acid diarrhoea with fatty liver and with gallstones suggests there are shared pathways, and further study may help in the understanding of these conditions.

lumen.¹ BAD has been categorised into three types that reflect the contribution of other gastrointestinal diseases. Type 1 occurs secondary to BA malabsorption in the terminal ileum due to inflammation or surgical resection, as commonly seen in Crohn's disease and is termed secondary bile acid diarrhoea (SBAD). Type 2 is the primary form (PBAD) in patients with a histologically normal ileum and type 3 is heterogeneous group of patients with BAD and another gastrointestinal diagnosis, most commonly cholecystectomy. PBAD has been identified



¹Division of Digestive Diseases, Imperial College London, London, UK

²Department of Gastroenterology, University Hospitals of Leicester NHS Trust, Leicester, UK

Correspondence to

Professor Julian RF Walters;
julian.walters@imperial.ac.uk



in excess of 25% of patients with diarrhoea-predominant irritable bowel syndrome and may have a prevalence of up to 1% in the population.^{2,3}

PBAD is not associated with a defect of BA absorption but the mechanism has been suggested to be a primary defect in feedback inhibition of hepatic BA synthesis, consequent to impairment in fibroblast growth factor 19 (FGF19) secretion by the ileum. FGF19 is a potent inhibitor of BA synthesis in liver and is transcriptionally regulated by BA binding to the farnesoid X receptor (FXR). Lower serum FGF19 levels in PBAD result in overproduction of BAs that saturate ileal absorption capacity and spill over into the colon.⁴ Diagnostic tests for BAD have been reviewed by Valentin *et al.*⁵ In the UK, the most widely used test for diagnosis of BAD is the ⁷⁵selenohomocholic acid taurate (SeHCAT) test, although this is not available in the USA and many other countries. The radiolabelled synthetic BA SeHCAT is administered on day 1 and retention measured 7 days later with a gamma camera. Increased loss of BA, with a retention of <15% is usually accepted as diagnostic of BAD and has a sensitivity of 100% and a specificity of 94% for BAD.⁶ BAD has been classified as mild with SeHCAT 7-day retention of 10%–15%, moderate with 5%–10% and severe if 0%–5%.³ The response rate to BA sequestrant therapy increases from 70% at a SeHCAT <15% to 96% at <5%.³

FGF19 controls BA homeostasis, and has metabolic effects on hepatic gluconeogenesis and lipid storage.⁷ In addition, hypertriglyceridaemia and obesity are associated with low FGF19.⁸ Low FGF19 in non-alcoholic fatty liver disease (NAFLD) has been shown to be related to disease progression to non-alcoholic steatohepatitis, fibrosis and cirrhosis in paediatric NAFLD, but its role in the more heterogeneous adult NAFLD population is unclear.⁹ For instance, an impaired hepatic response to FGF19 has been identified in some patients with NAFLD.¹⁰

Furthermore, a common genetic variant of FXR is associated with low FGF19 and gallstones.¹¹ Cholecystectomy has long been known to be a risk factor for BAD, but the mechanism of this remains unknown. However, the connection between these conditions and FGF19 is yet to be fully characterised.

When considering conditions that may be associated with BAD, there are those that may be linked by a shared pathogenesis in low FGF19, as already described, but there are others that may be caused by BAD by increased BA exposure in the colon. Microscopic colitis produces diarrhoea, which is indistinguishable from BAD symptomatically. Budesonide, in controlled release formulation, has been shown to reduce diarrhoea and increase SeHCAT retention, raising the possibility that, in a subset of patients at least, BAD is the mechanism of diarrhoea in microscopic colitis.¹² At high concentrations, BAs can be mutagenic and increased faecal BAs have been reported in patients with colorectal cancer and adenomas.¹³ Theoretically, the increased concentration of BAs in the colon as a consequence of BAD could

be a risk factor for colorectal carcinoma (CRC) and adenomas.

From these findings, we hypothesised that BAD could commonly coexist with conditions such as hypertriglyceridaemia, NAFLD and gallstones which may share pathophysiological mechanisms. In addition, we also hypothesised that there would be an increased incidence of microscopic colitis and colorectal adenomas in patients with a SeHCAT retention of <15%. Using the cohort of patients with chronic diarrhoea that we have assembled, who have all undergone SeHCAT testing for diagnosis of BAD, we looked for associations between these disorders, by comparing the prevalence in patients with and without BAD.

METHODS

Identification of patients

Results for patients undergoing SeHCAT tests to investigate symptoms of chronic diarrhoea at Imperial Healthcare NHS Trust have been collected prospectively since 2009. Patients who had a SeHCAT test elsewhere and were referred for specialist care were also added to the database, as were patients who had SeHCAT tests before this time but were under follow-up in our clinic during this period. A SeHCAT 7-day retention of <15% was taken as diagnostic as BAD. Many of these patients have been included in previous reports.^{14,15} We have performed a further retrospective analysis to look for specific associated conditions.

Categorisation of BAD

Patients with a SeHCAT <15% were categorised as type 1, 2, 3 BAD. This was performed both at the time of addition to the database and retrospectively at the time of study analysis by examination of outpatient clinic letters, clinical imaging, endoscopy and histology reports during the period 2009–2014. Letters and reports that quoted findings that predated this period were also included. Patients with terminal ileal resection or ileal Crohn's disease were recorded as type 1. The presence of any other gastrointestinal disease or surgery distal to the pylorus, including cholecystectomy was recorded at type 3. Patients with no evidence of another gastrointestinal disease were categorised as type 2 PBAD.

Identification of associated conditions

Clinical information was searched for on a variety of hospital clinical systems using the patient's unique hospital number. Information of significant comorbidities, including liver disease, was also reviewed from the available information; patients were excluded if another liver disease such as cirrhosis had been diagnosed. The following information was obtained from the electronic patient record systems: clinical biochemistry (only the samples from the nearest date to the SeHCAT test within 6 months were used), alanine aminotransferase (ALT, IU/L), triglycerides (TG, mmol/L); clinical imaging (at any time), presence of fatty liver on ultrasound, MRI or



CT scan, presence of gallstones or a cholecystectomy on ultrasound, MRI or CT scan (patients with no available imaging but known to have a cholecystectomy, were also included); total number of polyps (for all colonoscopies reported), size of largest polyp, presence of colorectal cancer (or reporting of a previous resected cancer), histology (specimens taken at any time).

Statistical methods

Non-parametric tests were used predominantly as the data were not normally distributed. Continuous data were compared with SeHCAT 7-day retention value using Spearman's rank correlation. Median SeHCAT values were described for categorical data. ORs and CIs for each disease were calculated for SeHCAT <15% and analysed using Fisher's exact test. Groups were compared for significant associations using Kruskal-Wallis and Mann-Whitney U tests. A p value of <0.05 was deemed as significant and was adjusted by Bonferroni correction, where multiple comparisons were made. All statistical analysis was performed using Prism V.6 software (GraphPad Software, La Jolla, California, USA).

RESULTS

Demographics

A total of 578 patients with chronic diarrhoea and SeHCAT values were included; 303 (52%) had positive results with a value <15%, defining BAD. Of these, 179 (31%) patients had PBAD and 124 (21%) had SBAD. The remaining 275 with SeHCAT >15% were controls; 126 patients had serum FGF19 measured as part of previous studies. The ethnicity of our patients, where this had been recorded, was 74% Caucasian, 15% Asian, 5% African-Caribbean and 6% mixed. Other demographics are shown in [table 1](#).

Low SeHCAT is associated with high ALT and imaging of hepatic steatosis

Four hundred and twenty-five patients had an ALT recorded, 184 had liver imaging and 176 had both. SeHCAT values correlated negatively with ALT ($r_s = -0.19$, $p < 0.0001$). Median values (and IQR) of ALT for groups with SeHCAT >15%, 10%–15%, 5%–10% and 0%–5% were 22 (16–30), 26 (18–36), 27 (20–40) and 26 (18–43),

$p = 0.008$, Kruskal-Wallis test. Comparing the groups with and without any form of BAD, a SeHCAT value <15% was associated with an ALT >31 IU/L (36% vs 21%, $p < 0.001$), OR 1.72 (95% CI 1.14 to 2.61, $p = 0.01$) and also with imaging showing steatosis together with ALT >31 IU/L (21% vs 7%, $p < 0.05$), OR 3.05 (95% CI 1.1 to 8.45, $p < 0.05$) ([Figure 1](#)).

Looking specifically at the PBAD subgroup, 128 of these patients had an ALT recorded and 57 had imaging. With types 1 and 3 (secondary) BAD excluded, SeHCAT value correlated negatively with ALT ($r_s = -0.23$, $p < 0.0001$). PBAD was associated with ALT >31 IU/L (43% vs 21%, $p < 0.001$), OR of 2.64 (95% CI 1.63 to 4.26, $p < 0.001$) and positive imaging together with ALT >31 IU/L (23% vs 7%, $p < 0.05$), OR 2.5 (95% CI 1.36 to 12.23, $p < 0.05$).

One hundred and twenty-three patients had both fasting FGF19 and ALT recorded, no significant correlation was found ($r_s = -0.08$, $p = 0.2$). However, FGF19 <70 pg/mL ($n = 10$) was predictive of an ALT >40 IU/mL (40% vs 12%, $p < 0.05$), OR 5.13 (95% CI 1.28 to 20.61, $p < 0.05$).

Low SeHCAT is associated with gallstones

One hundred and eighty-three patients had imaging that reported on the gallbladder, of which nine showed the presence of polyps. These were excluded, leaving 176 for further analysis. Of these, 103 (59%) had a positive SeHCAT scan <15%, 47 (27%) had gallstones, 12 (7%) had a cholecystectomy, so that 59 (34%) had either gallstones or cholecystectomy. There was no significant difference in the rate of gallstones or cholecystectomy by gender (64% vs 72%, $p = 0.2$), but mean age in the gallstones/cholecystectomy group was higher (50 vs 57 years, $p < 0.005$).

The median SeHCAT for those with gallstones or cholecystectomy was significantly lower than those without (7.2% vs 14%, $p < 0.001$). With cholecystectomy excluded, the median SeHCAT was still lower for those with gallstones (3.8% vs 14%, $p < 0.0001$). Overall, a SeHCAT value of <15% was associated with an increased risk of gallstones or cholecystectomy (OR 2.0, 95% CI 1.04 to 3.92, $p < 0.05$, [figure 2](#)) and the presence of PBAD was associated with gallstones, although this did not reach statistical significance (OR 1.98, 95% CI 0.65 to 5.99, $p = 0.23$).

Table 1 Demographics of population by SeHCAT result

	Controls (SeHCAT >15%)	BAD (SeHCAT <15%)	SeHCAT 15%–10%	SeHCAT 10%–5%	SeHCAT <5%
N	275	303	83	92	128
Type (n) 1/2/3	na	39/196/68	6/60/17	6/66/20	27/70/31
% female	64	60.7	59	59.8	62.5
Mean age (years)	48.7	52.1	55.3	50.8	51
Mean FGF19 (pg/mL)	302.1	166.6	193.6	185.9	127.6
Number with FGF19	54	72	16	30	26

SeHCAT, ⁷⁵selenohomocholeic acid taurate.




Figure 1 (A) Proportion of patients displayed by 75 selenohomocholic acid taurate (SeHCAT) positivity (<15%) with imaging reporting hepatic steatosis (imaging), ALT \geq 31 IU/L or both steatosis on imaging and ALT >31 IU/L (both). (B) Proportion of patients displayed by BAD type and controls (SeHCAT >15%) with imaging reporting hepatic steatosis (imaging), ALT \geq 31 IU/L or both steatosis and ALT >31 IU/L (both). (C) OR (95% CI) of SeHCAT <15% (BAD) or primary BAD (PBAD) and ALT >31 IU/L, or imaging of hepatic steatosis and ALT \geq 31 IU/L (both). (D) Correlation of SeHCAT 7-day retention (%) with ALT (IU/L), with linear regression fit line shown, r_s =Spearman's rank correlation. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001.

Low SeHCAT is associated with serum high TG

Two hundred and thirty-nine patients had serum TG measured. An analysis of 106 of them has been performed before.¹⁵ PBAD was significantly associated with a higher TG (mean 1.87 (95% CI 1.58 to 2.16) vs 1.29 (1.12 to 1.47) mmol/L, p <0.001). The ORs for patient with a positive SeHCAT having a TG \geq 1.7 or >2.4 mmol/L were 3.3 (p <0.001) and 3.1 (p <0.01), respectively (figure 3). Two hundred and nine patients had low-density lipoprotein recorded, and this correlated positively with SeHCAT, $r_s=0.14$, p <0.05.

One hundred and four patients had ALT, TG and gallbladder imaging recorded. Sixty-three of these patients had a SeHCAT <15% and 41 >15%. The OR of transaminasaemia, hypertriglyceridaemia and gallstones occurring together in patients with BAD compared with controls with a SeHCAT >15% was 2.7 (95% CI 0.29 to 25.01). The Fisher's exact test was $p=0.65$ (non-significant).

Low SeHCAT is not associated with colonic cancer, polyps or microscopic colitis

Three hundred and twenty-eight patients without inflammatory bowel disease (IBD) had a completed colonoscopy, of which 172 had a SeHCAT <15% and 156 had a SeHCAT >15%. The SeHCAT 7-day value did not correlate with number of polyps, the number of polyps >1 cm or the number with colorectal cancer. Demographics of this cohort and incidence of colonic adenomas or cancer by SeHCAT result are shown in table 2.

Two hundred patients had colonic biopsies, and 74 had ileal biopsies. Thirty-two patients were previously excluded due to the presence of IBD. One hundred one patients had a SeHCAT \geq 15% and four of these had histology positive for microscopic colitis. Ninety-nine patients had a SeHCAT diagnostic of BAD (<15%) and five of these were positive for microscopic colitis. Therefore, there was




Figure 2 (A) Proportion of patients displayed by ⁷⁵selenohomocholeic acid taurate (SeHCAT) 7-day retention value with cholecystectomy (CCX), gallstones (with cholecystectomy excluded) (GS) or cholecystectomy and gallstones combined (CCX+GS). (B) ORs (95% CI) of SeHCAT <15% with CCX, GS or CCX+GS. ns, non-significant, *p<0.05, **p<0.01, ***p<0.001.

no significant difference in the incidence of microscopic colitis in patients with SeHCAT <15%.

DISCUSSION

In view of possible shared pathophysiological mechanisms, we hypothesised that BAD (in particular PBAD), hypertriglyceridaemia, NAFLD and gallstones could be associated. Here, we report that BAD, as defined by SeHCAT testing, does more commonly coexist with hepatic steatosis (as suggested by a raised ALT and liver imaging (OR 3.0)), hypertriglyceridaemia (OR 3.3) and gallstones or cholecystectomy (OR 2.0).

The rationale for NAFLD being associated with BAD comes from the known association of both these diseases with hypertriglyceridaemia and obesity. In our previous publication including many of the patients in the current study,¹⁴ we found that overall SeHCAT and body mass index (BMI) values showed a significant, negative association ($r_s = -0.21$, $p = 0.02$). Obesity is clearly a plausible confounding factor in this present study; in 106 patients with available BMI data, there is an association of BMI and ALT ($r_s = 0.15$), which is of borderline significance ($p = 0.07$). It would be of interest to perform an analysis on a larger series having sufficient power to determine the possible causal relationships contributing to these associated disorders.

It is plausible that a reduced FGF19 is a pathogenic factor in both diseases as well, since it is associated with obesity, hepatic insulin resistance and NAFLD in paediatric patients.⁹ That study also reported a significant negative correlation between FGF19 and ALT, similar to our reported negative correlation of SeHCAT value and ALT, suggesting that the role of FGF19 could be of importance.⁹ Another recent study, also in paediatric patients, also showed low serum FGF19 in patients with non-alcoholic steatohepatitis (NASH) and raised levels of

serum BAs, which were linked to differences in the gut microbiome.¹⁶ It is of interest to note that both PBAD and NASH respond to the FXR agonist, obeticholic acid, which stimulates FGF19.^{17,18} We did not find an association of FGF19 with ALT using the 30 IU/L cut-off, but only at a higher value of ≥ 40 IU/L, with an FGF19 value of <70 pg/mL. There are multiple factors affecting FGF19 signalling, and some of these will affect the hepatic response to circulating levels FGF19, as has been shown previously.¹⁰ A prospective study, currently in progress, will help define these further.

The mechanism of higher serum TG in patients with BAD is seemingly paradoxical, since in a large population study, TGs were unaffected by FGF19.⁸ In the same patient group as the current study, we have recently described a positive correlation with SeHCAT and TG, but a negative correlation with FGF19 and TG.¹⁵ Furthermore, 30% of patients with a SeHCAT <15% had a high FGF19 and high TG. It appears there are likely to be several different causes of PBAD, including low fasting and stimulated FGF19, and hepatic resistance, suggesting the disease associations are likely to vary according to the underlying pathogenesis.

The finding that median SeHCAT values are lower in patients with gallstones, who have not had a cholecystectomy, is intriguing as the mechanism behind postcholecystectomy diarrhoea is not understood. It is associated with increased 7α -OH-4-cholesten-3-one (C4), indicating that increased BA production is a factor, but FGF19 does not change significantly postcholecystectomy.¹⁹ Our data suggest that patients with BAD are predisposed to gallstone disease, and probably subsequent cholecystectomy. Suppressing serum FGF19 with BA sequestrants has much larger effect on serum C4 in healthy volunteers, with an 87% reduction in serum FGF19 creating an 18-fold increase in C4.²⁰ It is possible that in susceptible




Figure 3 Correlation of 75 selenohomocholic acid taurate (SeHCAT) 7-day retention (%) with low-density lipoprotein (LDL) cholesterol (A) and triglycerides (TG) (B) with linear regression fit line shown, r_s =Spearman's rank correlation. (C) OR (95% CI) of SeHCAT <15% (bile acid diarrhoea (BAD)) and TG >1.7 or >2.4 mmol/L. (D) Median TG (IQR) of patients with SeHCAT \geq 15% (controls) and displayed by BAD type and compared with controls. ns, non-significant, * $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.

individuals with a reduced SeHCAT retention, the small decrease in FGF19 caused by cholecystectomy, creates a much larger increase in BA production, causing BAD. Equally, it is possible that these patients had diarrhoea predated their cholecystectomy.

In addition, we hypothesised that there would be an increased incidence of microscopic colitis and colorectal adenomas in patients with increased colonic BA loss. In our relatively large series of patients with colonoscopy (328) and colonic histology (200), the proportion of patients with either colonic adenoma/cancer or microscopic colitis was remarkably similar between patients with SeHCAT <15% and those \geq 15%. The proportion of

patients with either colonic adenoma/cancer or microscopic colitis was 25% and 4%, which is a little lower than found in a recent series of colonoscopies in 130 204 patients with chronic diarrhoea that reported rates of 29% and 8.6%.²¹

There were a number of limitations placed on this study due to its retrospective design. In particular, we cannot be certain that the patients presented here as having NAFLD do not have another cause of their raised ALT or steatosis. Alcohol consumption, comprehensive viral hepatitis serology and liver biopsy results were not routinely collected, although patients were excluded if a liver disease other than NAFLD had been diagnosed

Table 2 Demographics and number of patients with colorectal cancer and polyps by SeHCAT retention at 7 days (%)

	SeHCAT<15%	SeHCAT≥15%	p Value
n	172	156	
Age (years)	49.7	50.9	0.62
Gender (n=male)	79	49	0.007
Number with polyps	43	34	0.51
Total number of polyps	88	83	0.53
Number of polyps ≥1 cm	3	5	0.39
Total number of polyps ≥1 cm	3	5	0.39
Number with cancer	1	1	0.95

p Values calculated by Fisher's exact test.

on the documentation reviewed. Ideally, a diagnosis of NAFLD would be by hepatic biopsy, or at least a validated non-invasive scoring system. We were limited to using ALT and imaging findings, as these are common tests that significant number of our patients had recorded. Ultrasound has sensitivity of 77%–100% depending on the degree of steatosis, and ALT can be normal in up to 23% of patients with biopsy-proven NAFLD.^{22 23} However, ALT is widely accepted as a marker of severity for NAFLD and regardless of the aetiology of the liver disease, the incidence was found to be higher in patients with BAD. It is also important to remember that our control patients also have chronic diarrhoea and are not healthy volunteers, and so there is likely to be an increased level of comorbidity in this group compared with the general population.

In conclusion, we have shown that BAD, and particularly PBAD, is associated with increased incidence of NAFLD, hypertriglyceridaemia and gallstones. The reason for these associations cannot be assumed to be due to low FGF19 alone; however, the BA/FXR/FGF19 pathway is central to all these conditions and merits further prospective study. There is great interest at present in the use of FXR agonists in the treatment of PBC and NASH and there are considerable implications for how this pharmacotherapy may affect the production, intestinal delivery and enterohepatic circulation of BAs, and how these will then change metabolism, the microbiome and functional bowel symptoms.

Contributors RNA and JRFW devised the study, collected and analysed the data and drafted the manuscript. JDN, IMJ, SSP and JF collected data, contributed to the analysis and to the critical revision of the manuscript.

Funding The study was sponsored by Imperial College London. JRFW has served as a speaker, a consultant and an advisory board member for Albireo AB, GE Healthcare, Intercept Pharmaceuticals and Pendopharm. RNA has been supported by research funding from Albireo and Intercept. SSP, IMJ and JDN were supported by the BROAD research fund and/or by BRET. JF has no relevant disclosures.

Disclaimer This manuscript has been written in compliance with the STROBE guidance for cohort studies without any exception.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Inquiries regarding access to the data should be addressed to the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Appleby RN, Walters JR. The role of bile acids in functional GI disorders. *Neurogastroenterol Motil* 2014;26:1057–69.
2. Slattery SA, Niaz O, Aziz Q, *et al*. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. *Aliment Pharmacol Ther* 2015;42:3–11.
3. Wedlake L, A'Hern R, Russell D, *et al*. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther* 2009;30:707–17.
4. Walters JR, Tasleem AM, Omer OS, *et al*. A new mechanism for bile acid diarrhoea: defective feedback inhibition of bile acid biosynthesis. *Clin Gastroenterol Hepatol* 2009;7:1189–94.
5. Valentin N, Camilleri M, Altayar O, *et al*. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. *Gut* 2016;65:1951–9.
6. Sciarretta G, Vicini G, Fagioli G, *et al*. Use of 23-selena-25-homocholytaurine to detect bile acid malabsorption in patients with ileal dysfunction or diarrhea. *Gastroenterology* 1986;91:1–9.
7. Fang Q, Li H, Song Q, *et al*. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. *Diabetes Care* 2013;36:2810–4.
8. Gälman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. *J Intern Med* 2011;270:580–8.
9. Wojcik M, Janus D, Dolezal-Oltarzewska K, *et al*. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents. *J Pediatr Endocrinol Metab* 2012;25:1089–93.
10. Schreuder TC, Marsman HA, Lenicek M, *et al*. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. *Am J Physiol Gastrointest Liver Physiol* 2010;298:G440–G445.
11. Hirobe-Jahn S, Harsch S, Renner O, *et al*. Association of FXR gene variants with cholelithiasis. *Clin Res Hepatol Gastroenterol* 2015;39:68–79.
12. Bajor A, Kilander A, Gälman C, *et al*. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. *Aliment Pharmacol Ther* 2006;24:1643–9.
13. Imray CH, Radley S, Davis A, *et al*. Faecal unconjugated bile acids in patients with colorectal cancer or polyps. *Gut* 1992;33:1239–45.
14. Pattni SS, Brydon WG, Dew T, *et al*. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. *Aliment Pharmacol Ther* 2013;38:967–76.
15. Johnston IM, Nolan JD, Pattni SS, *et al*. Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary Bile Acid Diarrhea. *Am J Gastroenterol* 2016;111:423–32.
16. Jiao N, Baker SS, Chapa-Rodriguez A, *et al*. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. *Gut* 2017. doi: 10.1136/gutjnl-2017-314307. [Epub ahead of print 3 Aug 2017].
17. Walters JR, Johnston IM, Nolan JD, *et al*. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. *Aliment Pharmacol Ther* 2015;41:54–64.



18. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, *et al.* Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015;385:956–65.
19. Barrera F, Azócar L, Molina H, *et al.* Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. *Ann Hepatol* 2015;14:710–21.
20. Lundåsen T, Gälman C, Angelin B, *et al.* Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. *J Intern Med* 2006;260:530–6.
21. Genta RM, Sonnenberg A. The yield of colonic biopsy in the evaluation of chronic unexplained diarrhea. *Eur J Gastroenterol Hepatol* 2015;27:963–7.
22. Lee SS, Park SH, Kim HJ, *et al.* Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. *J Hepatol* 2010;52:579–85.
23. Fracanzani AL, Valenti L, Bugianesi E, *et al.* Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology* 2008;48:792–8.

Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis

Richard N Appleby, Jonathan D Nolan, Ian M Johnston, Sanjeev S Pattni, Jessica Fox and Julian RF Walters

BMJ Open Gastroenterology: 2017 4:
doi: 10.1136/bmjgast-2017-000178

Updated information and services can be found at:
<http://bmjopengastro.bmj.com/content/4/1/e000178>

These include:

References

This article cites 22 articles, 3 of which you can access for free at:
<http://bmjopengastro.bmj.com/content/4/1/e000178#ref-list-1>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
[Open access](#) (36)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>